Rotateq

Description

Rotavirus Vaccine, Live, Oral, Pentavalent

RotaTeq is a live, oral pentavalent vaccine that contains 5 live rotaviruses and is indicated for prevention against Rotaviral Gastroenteritis in infants and children caused by the serotypes G1, G2, G3 and G4.

Immunization guideline:

• Infants should receive 3 doses of Rotateq orally starting at 6 weeks of age at subsequent intervals of 4-10 weeks.

• The third dose should not be given after 32 weeks of age.

• If for any reason an incomplete dose is administered (e.g., infant spits or regurgitates the vaccine), a replacement dose is not recommended.

• The infant should continue to receive any remaining dose in the vaccination series.

• Infants should receive same type of Rotavirus vaccine for all the doses. They should not be interchanged with different brands.

• Rotateq can be administered with Diptheria and Tetanus toxoids and acellular pertussis (DTaP) vaccine, inactivated Polio vaccine, Haemophilus influenzae type b conjugate vaccine and Pneumococcal conjugate vaccine.

• It is better to administer OPV two weeks later than RV vaccine for better immune response for Rotavirus vaccine.

For latest IAP updates see revised immunization schedule.

Additional information

vaccine-type

Rotavirus

manufacturer

Merck Sharp & Dohme Corp

country-of-manufacture

USA

pharmaceutical-form

Liquid

package-size

1 Dose

route-of-administration

Oral

preservative

None

Contraindications

A demonstrated history of hypersensitivity to any component of the vaccine. Infants who develop symptoms suggestive of hypersensitivity after receiving a dose of RotaTeq should not receive further doses of Rota Teq.